Effects of sodium glucose cotransporter 2 inhibitors and pioglitazone on FIB‐4 index in metabolic‐associated fatty liver disease
Effects of sodium glucose cotransporter 2 inhibitors and pioglitazone on FIB‐4 index in metabolic‐associated fatty liver disease
复制标题
DOI：
10.1111/hepr.13898
复制
发表时间：
2023-03
影响因子：
4.2
通讯作者：
Masaaki Mino;Eiji Kakazu;Akitoshi Sano;H. Katsuyama;M. Hakoshima;H. Yanai;Yoshihiko Aoki;M. Imamura;Taiji Yamazoe;Taizo Mori;Sachiyo Yoshio;J. Inoue;A. Masamune;T. Kanto
中科院分区：
文献类型：
--
作者：
Masaaki Mino;Eiji Kakazu;Akitoshi Sano;H. Katsuyama;M. Hakoshima;H. Yanai;Yoshihiko Aoki;M. Imamura;Taiji Yamazoe;Taizo Mori;Sachiyo Yoshio;J. Inoue;A. Masamune;T. Kanto
钠 - 葡萄糖协同转运蛋白2抑制剂（SGLT2is）和噻唑烷二酮类抗糖尿病药物对非酒精性脂肪性肝病和2型糖尿病（T2DM）患者的肝功能障碍具有有益作用。我们旨在确定这些药物在治疗代谢功能障碍相关脂肪性肝病（MAFLD）和T2DM患者的肝脏疾病方面的疗效。
The antidiabetic drugs sodium glucose cotransporter 2 inhibitors (SGLT2is) and thiazolidinediones have beneficial effects on the liver dysfunction of patients with nonalcoholic fatty liver disease and type 2 diabetes mellitus (T2DM). We aimed to determine the efficacy of these drugs for the treatment of liver disease in patients with metabolic dysfunction‐associated fatty liver disease (MAFLD) and T2DM.